Camber Pharmaceuticals Launches Generic Phenergan®
Piscataway, NJ, May 3, 2023–Camber Pharmaceuticals is pleased to announce the addition of Promethazine HCI Suppositories, USP to its current portfolio.
Promethazine HCI Suppositories, USP are used to treat allergy symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes. It also prevents motion sickness, and treats nausea and vomiting or pain after surgery. It is also used as a sedative or sleep aid.
Click here to read the complete indication and usage for Promethazine HCI Suppositories, USP.
Promethazine HCI Suppositories, USP are available in 12.5 and 25 mg strengths in 12 count boxes.
To find out more about Promethazine HCI Suppositories, USP please visit www.camberpharma.com
Recent articles
- New to Camber’s Portfolio: Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
- Camber Pharmaceuticals Honored as Second Merit Finalist at 2026 DIANA Awards
- Camber Launches Nitazoxanide Tablets
- Cisatracurium Besylate Injection, USP Added to Camber’s Portfolio
- Camber Welcomes Summer 2026 Intern Class
- Camber Launches 5 Generics in May






